CureVac
Sven Koch is an accomplished immunologist with extensive experience in both academic and industry settings. Currently serving as Director of Immuno-Monitoring at CureVac since September 2020, Koch has held various significant roles including Associate Director of Immuno-Monitoring and Head of Biomarkers & Immunoanalysis at the same company. Prior experiences include Head of Translational Research at CatalYm GmbH and Laboratory Head Clinical Bioanalytics at Sandoz. Koch's research focuses on the identification of novel biomarkers and immune responses in clinical trials involving mRNA-based vaccines and therapeutics. With a PhD in Biology/Immunology from the University of Tübingen and a strong background in experimental immunology, Koch has contributed to the field through pivotal research and leadership roles.
This person is not in any teams
This person is not in any offices
CureVac
7 followers
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.